The 2009 American Society of Hematology (ASH) annual meeting introduced novel strategies for the treatment of acute leukemia. Targeted inhibitors for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) represent the future of these malignancies. Inclusion of targeted treatment to combination chemotherapy may translate into improved cure rates. The most clinically relevant abstracts, all of which are published in the November 2009, 114 issue of Blood, are summarized below and are identified here by their abstract numbers.
ASJC Scopus subject areas